Literature DB >> 3961167

Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B.

A Shirkhoda, G Lopez-Berestein, J M Holbert, M A Luna.   

Abstract

Disseminated fungal disease, predominantly involving liver and spleen, developed in eight patients with hematologic malignancies. Because the patients failed to respond to standard antifungal drugs, they were treated with liposomal amphotericin B (L AmpB). Before therapy began, the diagnosis was confirmed histologically and the patients underwent abdominal computed tomography (CT), which indicated hepatosplenomegaly with or without multiple microabscesses in the liver and spleen. After each course of treatment with L AmpB, patients underwent CT, followed by either open or CT-guided percutaneous aspiration biopsy of the liver. Post-treatment CT showed partial regression of lesions in six patients and persistence in two. In all patients a liver biopsy confirmed that the lesions noted after treatment were due to granulomas or focal areas of fibrosis compatible with healing. Thus, the persistence of multiple defects on enhanced scans in two patients was not an indication of persistent abscesses. Clinical response was an additional important factor. Close clinical and pathologic correlation in addition to CT scanning are required in the follow-up of hepatosplenic fungal infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3961167     DOI: 10.1148/radiology.159.2.3961167

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Successful treatment of focal hepatic candidiasis with liposomal amphotericin B.

Authors:  B O'Connell; G Crotty; M T Cafferkey; R Stephens; G S McDonald; S R McCann
Journal:  Ir J Med Sci       Date:  1992-12       Impact factor: 1.568

3.  Hepatosplenic candidasis, a fatal disease?

Authors:  A Loeliger; M van Leeuwen; M Rozenberg-Arska; A W Dekker
Journal:  Infection       Date:  1992-11       Impact factor: 3.553

4.  Embryonated eggs as an alternative infection model to investigate Aspergillus fumigatus virulence.

Authors:  Ilse D Jacobsen; Katharina Grosse; Silvia Slesiona; Bernhard Hube; Angela Berndt; Matthias Brock
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

5.  In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex.

Authors:  K Mitsutake; S Kohno; Y Miyazaki; T Noda; H Miyazaki; T Miyazaki; M Kaku; H Koga; K Hara
Journal:  Mycopathologia       Date:  1994-10       Impact factor: 2.574

6.  Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.

Authors:  P C Gokhale; R J Barapatre; S H Advani; N A Kshirsagar; S K Pandya
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 8.  Liposomes in treatment of infectious diseases.

Authors:  F Emmen; G Storm
Journal:  Pharm Weekbl Sci       Date:  1987-06-19

9.  Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

Authors:  M A Amantea; R A Bowden; A Forrest; P K Working; M S Newman; R D Mamelok
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.